FDA responds on behalf of chronic pain patients who require opioids to treat their pain

https://www.usatoday.com/videos/news/politics/2018/07/02/fda-chief-says-long-term-opioid-prescriptions-needed-some-chronic-pain-patients/752552002/

A VOICE OF REASON

As I said in my June blog, if we want change, we are obliged to share our 
unique individual circumstances and our life encounters. If you have been affected by having your opioids restricted, if you want pain management that fits within your personal framework, it’s time to use your voice.

Hope has turned in to reality; the FDA is listening! 

Our voice is being heard, so let’s keep using it.

ID: FDA-2018-N-1621-0001

The Food and Drug Administration (FDA)

“Patient-Focused Drug Development for Chronic Pain.” The public meeting will provide patients (including adult and pediatric patients) with an opportunity to present to FDA their perspectives on the impacts of chronic pain, views on treatment approaches for chronic pain, and challenges or barriers to accessing treatments. FDA is particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies.

Comment Now!

Due Sep 10 2018, at 11:59 PM ET

https://www.regulations.gov/document?D=FDA-2018-N-1621-0001

Adversity is only an obstacle if we fail to see opportunity."

Additional Reading:

Opportunity Knocks Again: Public Comments on Patient-Focused Drug Development for Chronic Pain (includes my comment)

In healing,

Celeste Cooper, RN / Author, Freelancer, Advocate

Think adversity?-See opportunity!

http://www.CelesteCooper.com

~ • ~ • ~ • ~ • ~ • ~

Learn more about Celeste’s books here. Subscribe to posts by using the information in the upper right hand corner or use the share buttons to share with others. 

The FM/a® Blood Test and Participation in Fibromyalgia Vaccine Study

The FM/a® Test is making a huge impact on the way fibromyalgia is diagnosed and now it is being used for very important research.

Download the Brochure

In November of 2017, I wrote about the exciting research that focuses on finding the cause and developing a treatment for fibromyalgia. (1) February of this year, I reported that genetic studies on fibromyalgia are well underway – with the assistance of the University of California, UCLA, and University of Illinois at Chicago. (2) In April of 2017, “Breaking News" included information relative to this announcement. (3)

Under contract with researchers from both UCLA and the University of Illinois College of Medicine Chicago, Campaign 250 will conduct Whole-Exome genetic testing on up to 250,000 patients who have received a positive FM/a® fibromyalgia diagnosis…

Based upon the findings of this testing and once treatment protocols have received regulatory and institutional approvals, FM/a® Test positive patients will be invited to participate in a fibromyalgia-specific vaccine clinical trial to reverse the biology of fibromyalgia…

I am excited to report that the long-term reduction in hyperglycemia in advanced type 1 diabetes using BCG vaccine found that after year 3, BCG lowered hemoglobin A1c (a blood test to monitor blood sugars over a period of time) to near normal levels for the next 5 years. That is a significant result. This same vaccine was reported in the above "Breaking News" statement. This is important because this old vaccine for tuberculosis now shows promise as treatment for numerous inflammatory and autoimmune diseases.

BCG = attenuated Mycobacterium bovis Bacillus Calmette Guérin (BCG) strain.

Professor Denise Faustman, specialist in immunology who is affiliated with Harvard Medical School and Massacheusetts General Hospital, was a lead researcher in the vaccine study for diabetes and she will lead the vaccine study for fibromyalgia. The only qualification to participate in this exciting research is to have tested positive with the FM/a Test.

“FM/a® is a multi-biomarker-based test which concerns immune system white blood chemokine and cytokine patterns. Patients with fibromyalgia have a significantly dysregulated pattern regarding these proteins.

Will you join me?

PLEASE VISIT

https://fmtest.com 

The blood test is now covered by most insurance, including CHAMPVA and Medicare.

Resources:

(1) The FM/a® Blood Test and Participation in Fibromyalgia Vaccine Study

(2) Update: Fibromyalgia FM/a Blood Test and EpicGenetics Landmark Clinical Research Efforts

(3) EpicGenetics Announces Major Clinical Study to Locate Genetic Markers Unique to People with Fibromyalgia and Explore New Treatment Approaches

Additional Information:

·        Peer-reviewed Medical Publications

·        Researchers Seek to Find Cause of Fibromyalgia via Genetic Testing

·        Learn More, including taking the first steps, information about the FM/a® Test and Frequently Asked Questions.   

In healing,

Celeste Cooper, RN / Author, Freelancer, Advocate

Think adversity?-See opportunity!

http://www.CelesteCooper.com

~ • ~ • ~ • ~ • ~ • ~

Learn more about Celeste’s books here. Subscribe to posts by using the information in the upper right hand corner or use the share buttons to share with others.